Filing Flows › BioMarin Pharmaceutical (BMRN) › Q2 2026 › vs Q2 2025
BioMarin Pharmaceutical (BMRN) Q2 2026 vs Q2 2025 (year over year)
BioMarin Pharmaceutical's revenue rose $164M (+20%) from $825M in Q2 2025 to $990M in Q2 2026. The biggest changes: Net product revenues +$171M (+21%); Royalty and other revenues −$7.1M (-57%). Operating margin 11.2% against 33.5% (-22.3 pts).
BioMarin Pharmaceutical, Q2 2026: revenue $990M (+20% year over year), operating margin 11.2%, net earnings $44.8M, operating cash flow $168M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 11.2% | 33.5% | -22.3 pts |
| Net margin | 4.5% | 29.1% | -24.6 pts |
| Free cash flow margin | 14.1% | 20.4% | -6.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| VOXZOGO | $253M | $221M | $31.1M | +14% |
| VIMIZIM | $194M | $215M | −$21.1M | -10% |
| NAGLAZYME | $135M | $129M | $6.4M | +5% |
| PALYNZIQ | $135M | $106M | $29.2M | +28% |
| GALAFOLD | $106M | $0 | $106M | — |
| BRINEURA | $51.4M | $48.7M | $2.7M | +5% |
| ALDURAZYME | $43.5M | $56.4M | −$12.9M | -23% |
| POMBILITI + OPFOLDA | $30.3M | $0 | $30.3M | — |
| KUVAN | $24.4M | $27.0M | −$2.6M | -10% |
| ROCTAVIAN | $11.7M | $9.2M | $2.5M | +27% |
| Net product revenues | $984M | $813M | $171M | +21% |
| Royalty and other revenues | $5.3M | $12.4M | −$7.1M | -57% |
| Revenue | $990M | $825M | $164M | +20% |
| Operating profit | $111M | $277M | −$166M | -60% |
| Costs & expenses | $879M | $549M | $330M | +60% |
| Pre-tax earnings | $61.4M | $298M | −$236M | -79% |
| Other expense, net | $49.5M | −$21.0M | $70.5M | — |
| Cost of revenue | $203M | $150M | $52.7M | +35% |
| Research & development | $207M | $161M | $45.6M | +28% |
| SG&A | $396M | $232M | $163M | +70% |
| Other operating costs | $73.5M | $4.8M | $68.6M | 15× |
| Net earnings | $44.8M | $241M | −$196M | -81% |
| Income tax | $16.6M | $57.3M | −$40.7M | -71% |
| Operating cash sources | $218M | $307M | −$88.5M | -29% |
| Depreciation & amortization | $97.6M | $18.6M | $79.1M | +426% |
| Share-based compensation | $75.7M | $47.5M | $28.2M | +59% |
| Working capital & other | $50.0M | $121M | −$71.4M | -59% |
| Operating cash flow | $168M | $185M | −$17.2M | -9% |
| Free cash flow (OCF − capex) | $139M | $168M | −$28.9M | -17% |
| Capital expenditures | $28.8M | $17.1M | $11.7M | +69% |
Questions
How much did BioMarin Pharmaceutical's revenue grow year over year in Q2 2026?
BioMarin Pharmaceutical's revenue rose $164M (+20%) from $825M in Q2 2025 to $990M in Q2 2026.
What drove BioMarin Pharmaceutical's revenue change in Q2 2026?
Net product revenues +$171M (+21%); Royalty and other revenues −$7.1M (-57%).